How to Taper Off Psychiatric Medications Safely: What You Need to Know

SSRI and SNRI discontinuation syndrome occurs when these medications are stopped abruptly or tapered too quickly. The syndrome is directly related to the medication's half-life — the time required for the body to eliminate half of the drug from the bloodstream. Medications with short half-lives produce faster onset of discontinuation symptoms; those with long half-lives produce slower, sometimes delayed onset.

Classic discontinuation symptoms include:

• Electric shock sensations (“brain zaps”) — brief, disorienting electrical-like sensations, typically in the head, that are among the most distressing and distinctive discontinuation symptoms
• Dizziness — often described as vertigo or a feeling of the ground shifting; worsened by eye movement
• Flu-like symptoms — fatigue, chills, muscle aches, nausea, sweating, without fever or actual illness
• Irritability and mood instability — rapid emotional shifts, heightened reactivity, tearfulness
• Rebound anxiety and depression — a surge of anxiety or depressive symptoms, sometimes more intense than the original condition
• Sleep disruption — vivid dreams, insomnia, hypersomnia

Brain zaps are among the most disorienting discontinuation symptoms and are often not adequately explained to patients. The proposed mechanism involves the serotonin transporter (SERT):

SSRIs work by blocking SERT — the protein that removes serotonin from the synaptic cleft. Over time on an SSRI, the brain downregulates SERT expression (fewer transporters) in response to the elevated synaptic serotonin. When the SSRI is removed abruptly, SERT expression bounces back, serotonin is rapidly removed from synapses, and the serotonergic system is suddenly hypersensitized.

The electrical sensations are thought to arise from this acute serotonergic fluctuation affecting the proprioceptive and vestibular pathways — hence the characteristic association with eye movement and changes in head position. They are generally benign but can be profoundly distressing, and some patients experience them for weeks to months after discontinuation.

Traditional tapering schedules — such as reducing by 25mg every 2 weeks — were developed empirically and do not account for the non-linear relationship between SSRI dose and serotonin transporter occupancy. The work of Horowitz and Taylor (published in The Lancet Psychiatry in 2019) provided the pharmacodynamic evidence for a fundamentally different approach: hyperbolic tapering.

The key insight: SSRIs occupy serotonin transporters in a hyperbolic dose-response curve, not a linear one. This means:

• Going from 200mg to 100mg (50% dose reduction) produces a much smaller change in SERT occupancy than going from 20mg to 10mg
• The final dose reductions — the last few milligrams — produce the greatest proportional changes in SERT occupancy and therefore the greatest discontinuation risk
• Reducing by equal milligram amounts throughout the taper dramatically overloads the lowest dose reductions relative to the neuropharmacological impact

The hyperbolic tapering approach resolves this by reducing by approximately 10% of the current dose at each step, not 10% of the original dose. This means the absolute mg reductions get smaller as the dose decreases — which is precisely what is needed to keep the pharmacodynamic impact roughly constant throughout the taper.

Implementation requires either liquid formulations, compounding pharmacies for very small doses, or using tablet-splitting techniques where feasible. The minimum hold at each step is generally 4 weeks — enough time for the brain to adapt to the new serotonergic state before the next reduction.

The 10% rule and 4-week holds are starting points, not rigid prescriptions. Individual variation in taper tolerance is real and significant:

• Duration of treatment — longer treatment duration is associated with greater adaptation of the serotonergic system and typically requires a slower taper
• Dose history — higher doses over longer periods may require longer holds and smaller steps, especially at the low end
• CYP450 enzyme variation — genetic variations in drug-metabolizing enzymes affect how quickly SSRIs are cleared, which influences both the effectiveness of the original dose and the speed with which the taper can proceed
• Clinical context — someone tapering during a period of life stress may need to slow or pause; someone who has been well-stabilized for years in a stable life context may tolerate a somewhat faster pace

The rule is: slow down if symptoms emerge. A taper is not a race. If significant discontinuation symptoms appear at any step, the appropriate response is to hold the current dose (not to go back up) and wait for symptoms to resolve before proceeding.

Antipsychotics: Dopamine Supersensitivity Psychosis

Antipsychotics work by blocking dopamine D2 receptors. Over time on antipsychotic therapy, the brain upregulates D2 receptor density in response to the sustained blockade. When an antipsychotic is discontinued too quickly, this receptor upregulation results in dopamine supersensitivity — a state in which dopamine has amplified effects. This can trigger psychotic symptoms even in people who have been fully stable on medication, making it look like a relapse when it is actually a pharmacologically-induced state caused by the withdrawal itself.

Antipsychotic tapers should always be slow, supervised, and conducted only after a documented period of sustained stability. The longer the duration of antipsychotic use, the higher the supersensitivity risk.

Benzodiazepines: A Medical Issue, Not a Willpower Issue

Benzodiazepine tapering is qualitatively different from other psychiatric medication tapers — it carries seizure risk and must be treated as a medical matter requiring professional supervision. Abrupt benzodiazepine discontinuation in a physically dependent individual can be fatal.

Benzodiazepines work by enhancing GABA-A receptor activity. Prolonged use causes GABA receptor downregulation and glutamate upregulation — the nervous system becomes hyperexcitable when the GABAergic enhancement is removed. Beyond seizure risk, benzodiazepine withdrawal produces a severe discontinuation syndrome: extreme anxiety, insomnia, tremor, sweating, muscle cramps, and perceptual disturbances.

Standard protocol involves switching to a long-acting benzodiazepine (usually diazepam/Valium or clonazepam) to allow a smoother taper, then reducing by approximately 5–10% every 1–2 weeks, with the pace driven entirely by symptom tolerance. This is a months-long process in most cases of significant physical dependence.

Mood Stabilizers: Lithium and Lamotrigine

Lithium discontinuation carries a specific, well-documented risk: rebound mania. Studies show that stopping lithium abruptly is associated with a manic episode within weeks in a significant proportion of people with bipolar disorder — at rates that exceed what would be expected from the underlying illness alone. This “rebound” exceeds the risk of a natural mood episode. Lithium should be tapered over a minimum of several weeks to months, with mood monitoring throughout.

Lamotrigine (Lamictal) carries a seizure threshold concern on discontinuation — rapid dose reduction can lower the seizure threshold, even in people with no seizure history. Tapering guidelines recommend reducing by no more than 50% per week over at least 2 weeks. This applies even in patients who are taking lamotrigine for mood, not seizure control.

Systematic tracking during a taper serves two purposes: it provides the data needed to distinguish discontinuation symptoms from relapse, and it gives the prescriber the information needed to adjust the schedule. Track daily:

• Mood — rate on a 1–10 scale (1 = severely depressed/anxious; 10 = fully stable). Look for trends over days, not single data points.
• Sleep — hours, quality, dreams, difficulty falling or staying asleep. Sleep disruption is one of the earliest and most sensitive discontinuation signals.
• Somatic symptoms — document any physical symptoms: dizziness, nausea, brain zaps, sweating, muscle aches. Time-stamp their onset relative to dose changes.
• Functional impairment — ability to work, care for family, maintain relationships. This is often the most clinically meaningful outcome measure.

Not all symptoms during a taper require stopping. These do:

• Suicidal ideation or thoughts of self-harm — any emergence during a taper warrants an urgent call to your prescriber, a pause in the taper, and a safety assessment
• Psychotic symptoms — any hallucinations, paranoid thinking, or disorganized thought during an antipsychotic taper is a medical emergency
• Mania or hypomania — elevated mood, decreased sleep need, racing thoughts, impulsivity, especially during lithium or mood stabilizer taper
• Seizure activity — any convulsive activity during a benzodiazepine or lamotrigine taper is an emergency; call 911
• Severe functional impairment — inability to work, care for children, or maintain safety warrants a taper pause

This is one of the most important clinical distinctions in tapering — and it directly determines whether to pause the taper, reverse it, or continue:

When in doubt, holding the taper for 4+ weeks and reassessing is the appropriate response. Time-course often clarifies the picture: discontinuation symptoms typically peak and then gradually resolve; relapse symptoms typically worsen over weeks without treatment.

Tapering is not only a pharmacological process — it is also a psychological one. The period of dose reduction is often when old symptoms resurface at lower intensity, old patterns reassert themselves, and the person discovers what their actual baseline functioning looks like without medication. Having a therapist during this period is not optional for people with significant mental health histories.

Specifically, CBT skills for anxiety and depression are directly applicable to managing the emotional component of tapering. Mindfulness-based approaches help distinguish physical discontinuation symptoms from emotional distress. Supportive therapy provides a space to process the anxiety and ambivalence that commonly accompanies medication discontinuation.

Some prescribers will be supportive of a tapering request; others will express concern or resist. Here are scripts for productive conversations in both scenarios:

• “I've been stable on [medication] for [X years] and I'd like to explore a supervised taper. I'd want to do this slowly — maybe 10% reductions over months — and I'm committed to pausing if symptoms emerge. Can we discuss what a safe plan would look like?”
• “I've read about hyperbolic tapering — the Horowitz and Taylor 2019 Lancet Psychiatry paper. I'm concerned that a standard linear taper might not account for the SERT occupancy curve. Can we design the taper to reduce by percentage rather than fixed milligrams?”
• “I understand there's a risk of relapse and I want to monitor carefully. I'd like to track mood and sleep daily and check in with you regularly. If I show signs of relapse, I'm willing to go back on the medication. I just want to try, responsibly.”
• If your prescriber declines entirely: “Can you help me understand what clinical factors make you concerned that a supervised taper isn't appropriate for my situation?” — this opens a conversation about the specific clinical contraindications rather than leaving you with an unexplained no.